The Nasdaq Biotechnology Index (NBI) launched in 1993, when the business was nonetheless within the midst of the unique “biotech revolution.” Since then, its constituent basket has swelled from roughly 100 elements to 274, reflecting the large development within the small cap area – the overwhelming majority of which has stemmed from IPOs on the Nasdaq Inventory Trade.
Because the biotech business enters a brand new part of development, it’s extra essential than ever for traders to think about their allocations towards the area.
Within the upcoming webcast, The Biotech Trek: A Quick Historical past from 1993 to 2021, Rene Reyna, Head of Thematic and Specialty Product Technique ETFs and Listed Methods, Invesco; and Mark Marex, Analysis & Growth Specialist, Nasdaq World Indexes, will talk about the regulatory, scientific, and demographic components driving right now’s development in biotech and why the Nasdaq Biotechnology Index’s methodology results in the perfect illustration of the sector.
The Nasdaq Biotechnology Index (NBI) has set the usual. NBI, which has a monitor report spanning practically three many years, is now the underlying index for the newly minted Invesco Nasdaq Biotechnology ETF (IBBQ).
One among eight globally listed ETFs now use NBI because the benchmark. For fund issuers, utilizing NBI as a biotech gauge is related on a number of fronts. First, its efficiency has been stellar. The index surged 370% through the 2010s, trouncing conventional healthcare indices within the course of. Second, though NBI is a big cap index, it’s a broad one. At this time it has 274 elements, up from simply 100 at the beginning of 2010. In different phrases, the index has captured the quickly increasing biotechnology area.
In actual fact, information verify NBI is a related benchmark for fund issuers seeking to present publicity past simply the biggest biotech names. NBI’s inclusion of mid- and small-cap names is essential as a result of it provides the index the pliability to make room for brand spanking new biotech shares. Because the begin of 2020, there have been 123 biotech IPOs, 120 of which listed on the Nasdaq. Knowledge point out issuers opting to make use of a Nasdaq index for a biotech ETF get a extra full view of the general marketplace for these shares.
NBI’s elements are research- and development-intensive. Within the biotech area, which is research-intensive itself, that’s a recipe for fulfillment. Moreover, a dedication to R&D helps corporations keep away from patent cliff vulnerabilities whereas making them extra engaging takeover targets.
Monetary advisors who’re concerned with studying extra in regards to the biotech sector can register for the Wednesday, June 30 webcast right here.
Learn extra on ETFtrends.com.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.